![]() |
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Department of Cell and Molecular Pharmacology and Experimental Therapeutics and Hollings Cancer Center, Medical University of South Carolina, Charleston, South Carolina (M.M.K., E.M.E., S.A.R.); and Department of Otolaryngology-Head and Neck Surgery, University of Virginia Health System, Charlottesville, Virginia (M.J.J.)
Signaling by the insulin-like growth factor (IGF)-1 receptor (IGF-1R) has been implicated in the promotion and aggressiveness of breast, prostate, colorectal, and lung cancers. The IGF binding proteins (IGFBPs) represent a class of natural IGF antagonists that bind to and sequester IGF-1/2 from the IGF-1R, making them attractive candidates as therapeutics for cancer prevention and control. Recombinant human IGFBP-2 significantly attenuated IGF-1-stimulated MCF-7 cell proliferation with coaddition of 20 or 100 nM IGFBP-2 (50 or 80% inhibition, respectively). We previously identified IGF-1 contact sites both upstream and downstream of the CWCV motif (residues 247-250) in human IGFBP-2 (J Biol Chem 276:2880-2889, 2001
20-fold decrease in IGF-1 binding affinity (IGFBP-2 EC50 = 0.35 nM and IGFBP-21-248 = 7 nM). Removal of the remainder of the C-terminal domain had no further effect on affinity (IGFBP-21-190 EC50 = 9.2 nM). In kinetic assays, IGFBP-21-248 and IGFBP-21-190 exhibited more rapid association and dissociation rates than full-length IGFBP-2. These results confirm that regions upstream and downstream of the CWCV motif participate in IGF-1 binding. They further support the development of full-length IGFBP-2 as a cancer therapeutic.
Address correspondence to: Dr. Steven A. Rosenzweig, Department of Cell and Molecular Pharmacology and Experimental Therapeutics, Medical University of South Carolina, 173 Ashley Ave., P.O. Box 250505, Charleston, SC 29425. E-mail: rosenzsa{at}musc.edu
This article has been cited by other articles:
![]() |
T. Fukushima, T. Tezuka, T. Shimomura, S. Nakano, and H. Kataoka Silencing of Insulin-like Growth Factor-binding Protein-2 in Human Glioblastoma Cells Reduces Both Invasiveness and Expression of Progression-associated Gene CD24 J. Biol. Chem., June 22, 2007; 282(25): 18634 - 18644. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Eiseman, J. Guo, R. K. Ramanathan, C. P. Belani, D. B. Solit, H. I. Scher, S. P. Ivy, E. G. Zuhowski, and M. J. Egorin Evaluation of Plasma Insulin-like Growth Factor Binding Protein 2 and Her-2 Extracellular Domain as Biomarkers for 17-Allylamino-17-Demethoxygeldanamycin Treatment of Adult Patients with Advanced Solid Tumors Clin. Cancer Res., April 1, 2007; 13(7): 2121 - 2127. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Sitar, G. M. Popowicz, I. Siwanowicz, R. Huber, and T. A. Holak Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins PNAS, August 29, 2006; 103(35): 13028 - 13033. [Abstract] [Full Text] [PDF] |
||||